{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-021169","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.289778+00:00","generated_at":"2026-06-05T10:35:03.653257+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acadia Pharma Q4 net income $45.8M; 2023 revenue $726.4M (+40%); FY2024 DAYBUE guide $370-420M","bullets":["Q4 2023 net income $45.8M ($0.28 EPS) vs net loss $41.7M ($0.26 loss) in Q4 2022.","Full year 2023 net loss $61.3M ($0.37 loss) vs net loss $216.0M ($1.34 loss) in 2022.","2023 total net product sales $726.4M (+40% YoY); DAYBUE $177.2M, NUPLAZID $549.2M (+6%).","FY2024 guidance: DAYBUE net sales $370-420M; NUPLAZID $560-590M; R&D $305-325M; SG&A $455-480M.","Phase 3 ADVANCE-2 (pimavanserin for negative schizophrenia) top-line results due by end of Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-021169","json":"https://secwatch.observer/filing/0000950170-24-021169.json","markdown":"https://secwatch.observer/filing/0000950170-24-021169.md","text":"https://secwatch.observer/filing/0000950170-24-021169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000095017024021169/0000950170-24-021169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000095017024021169/acad-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T10:35:03.653257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04a49486a12defecb2d7e498aa4677a8f18b8363","claim":"ACADIA PHARMACEUTICALS INC updated its Full Year 2024 guidance (initiated).","evidence_excerpt":"Full Year 2024 Financial Guidance • DAYBUE net product sales in the range of $370 to $420 million. • NUPLAZID net product sales in the range of $560 to $590 million. • GAAP R&D expense in the range of $305 to $325 million. • GAAP SG&A expense in the range of $455 to $480 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000095017024021169/0000950170-24-021169-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2024"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"eff5775aa25bb036641f9fc81e688df5fb327b38","claim":"ACADIA PHARMACEUTICALS INC reported fourth quarter and full year ended December 31, 2023 results: revenue $231.0 million for the fourth quarter of 2023 and $726.4 million for the full year 2023, net income net income of $45.8 million for the fourth quarter of 2023 and net loss of $61.3 million for the full year 2023, EPS $0.28 per common share for the fourth quarter and $(0.37) per common share for the full year.","evidence_excerpt":"Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000095017024021169/0000950170-24-021169-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$231.0 million for the fourth quarter of 2023 and $726.4 million for the full year 2023"},{"label":"Net income","value":"net income of $45.8 million for the fourth quarter of 2023 and net loss of $61.3 million for the full year 2023"},{"label":"EPS","value":"$0.28 per common share for the fourth quarter and $(0.37) per common share for the full year"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}